在阿尔茨海默病中TREM2向治疗的潜力和挑战:来自INVOKE-2研究的见解
Ya-Nan Ma1, Xiqi Hu1, Kenji Karako2
1Department of Neurosurgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
Frontiers in aging neuroscience
|May 12, 2025
概括
准TREM2 (在骨髓细胞2表达的触发受体) 对阿尔茨海默病 (AD) 治疗有希望. 然而,最近的试验结果强调需要优化治疗时间,剂量和患者选择,以实现未来的治疗成功.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其全球流行率正在增加.
- 微质TREM2 (在骨髓细胞2表达的触发受体) 是神经炎症和AD病理蛋白质清除的关键调节者.
- 开发有效的AD治疗方法仍然是一个关键的未满足的医疗需求.
研究的目的:
- 检查TREM2在阿尔茨海默氏症病原发生中的作用.
- 评估针对TREM2.2的INVOKE-2临床试验的结果.
- 讨论基于TREM2的阿尔茨海默病治疗方法的未来策略.
主要方法:
- 关于AD中TREM2功能的科学文献的综述.
- 对TREM2抗体AL002.00的INVOKE-2临床试验结果的分析.
- 讨论影响治疗功效的因素.
主要成果:
- TREM2在微质功能和AD病理学中发挥着重要作用.
- INVOKE-2试验没有达到其主要终点,这表明当前的TREM2向方法存在挑战.
- 几个因素,包括治疗时间和患者遗传学,可能会影响TREM2治疗结果.
结论:
- TREM2仍然是阿尔茨海默病的潜在治疗点.
- 优化治疗参数和患者分层是未来临床成功的关键.
- 组合疗法可能会提高基于TREM2的干预措施的疗效.
更多相关视频
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
3.6K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.5K
相关概念视频
01:22Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
01:26Alzheimer's Disease: Overview
336
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336